Neurocognitive Impairment in Ugandan Children with Sickle Cell Anemia Compared to Sibling Controls: A cross-sectional study.

Journal: medRxiv : the preprint server for health sciences

Volume: 

Issue: 

Year of Publication: 

Affiliated Institutions:  Department of Psychiatry, Makerere University College of Health Sciences, Kampala, Uganda. Department of Neurology, Columbia University Vagelos Medical Center, New York, United States. Department of Mental Health and Community Psychology, Makerere University College of Social Sciences, Kampala, Uganda. Global Health Uganda, Kampala, Uganda. Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda. Directorate of Paediatrics and Child Health, Mulago National Referral Hospital. Department of Pediatrics, Columbia University Vagelos Medical Center, New York, United States.

Abstract summary 

Neurocognitive function in Ugandan children aged 1-12 years with sickle cell anemia (SCA) were compared to their non-SCA siblings to identify risk factors for disease-associated impairment.This cross-sectional neurocognitive function study of children with SCA (N=242) and non-SCA siblings (N=127) used age- and linguistically-appropriate standardized tests of cognition, executive function and attention for children ages 1-4 and 5-12 years. Test scores were converted to locally derived age-normalized z-scores. The SCA group underwent standardized stroke examination for prior stroke and transcranial doppler ultrasound (TCD) to determine stroke risk by arterial flow velocity.The SCA group was younger than siblings (mean ages 5.46±3.0 versus 7.11±3.51 years, respectively; p <.001), with lower hemoglobin concentration (7.32±1.02 vs. 12.06±1.42, p <.001). Overall cognitive SCA z-scores were lower: -0.73 ±0.98 vs. siblings -0.25 ±1.12 (p<.001), with comparable findings for executive function of -1.09±0.94 versus -0.84±1.26 (p=0.045), respectively. Attention z-scores for ages 5-12 for the SCA group and controls were similar: -0.37±1.4 vs. -0.11±0.17 (p=.09). Overall differences by SCA status were largely driven by the older age group, as z-scores in the younger sub-sample did not differ from controls. Analyses revealed the strongest predictors of poor neurocognitive outcomes among the SCA sample to be the disease, age and prior stroke (each p<.001). Impact from anemia and SCA were indistinguishable.Neurocognitive testing in children with SCA compared to non-SCA siblings revealed poorer SCA-associated functioning in children older than age 4. Results indicate need for trials assessing impact from disease modification for children with SCA.

Authors & Co-authors:  Bangirana Paul P Boehme Amelia K AK Birabwa Annet A Opoka Robert O RO Munube Deogratias D Mupere Ezekiel E Kasirye Phillip P Muwanguzi Grace G Musiimenta Maxencia M Ru George G Green Nancy S NS Idro Richard R

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311–323.
Authors :  12
Identifiers
Doi : 2023.11.09.23298329
SSN : 
Study Population
Male,Female
Mesh Terms
Other Terms
Neurocognition;Neurocognitive impairment;Pediatric sickle cell;Sickle cell anemia;Sub-Saharan Africa
Study Design
Cross Sectional Study
Study Approach
Country of Study
Uganda
Publication Country
United States